Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
113 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Muscular Dystrophy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Muscular Dystrophy - Pipeline Review, H2 2014', provides an overview of the Muscular Dystrophy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscular Dystrophy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Muscular Dystrophy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Muscular Dystrophy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Muscular Dystrophy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Muscular Dystrophy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Muscular Dystrophy Overview 11 Therapeutics Development 12 Pipeline Products for Muscular Dystrophy - Overview 12 Pipeline Products for Muscular Dystrophy - Comparative Analysis 13 Muscular Dystrophy - Therapeutics under Development by Companies 14 Muscular Dystrophy - Therapeutics under Investigation by Universities/Institutes 16 Muscular Dystrophy - Pipeline Products Glance 17 Clinical Stage Products 17 Early Stage Products 18 Muscular Dystrophy - Products under Development by Companies 19 Muscular Dystrophy - Products under Investigation by Universities/Institutes 21 Muscular Dystrophy - Companies Involved in Therapeutics Development 22 Acceleron Pharma, Inc. 22 aTyr Pharma, Inc. 23 Benitec Biopharma Limited 24 Bioblast Pharma Ltd. 25 Calzada Limited 26 Evotec AG 27 F. Hoffmann-La Roche Ltd. 28 Fate Therapeutics, Inc. 29 Genethon 30 Genzyme Corporation 31 Isis Pharmaceuticals, Inc. 32 Marina Biotech, Inc. 33 Novogen Limited 34 Prosensa Therapeutics B.V. 35 Prothelia, Inc. 36 SanBio, Inc. 37 Santhera Pharmaceuticals Holding AG 38 Sarepta Therapeutics, Inc. 39 Takeda Pharmaceutical Company Limited 40 Valentia Biopharma S.L. 41 Zambon Company S.p.A. 42 Muscular Dystrophy - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 ACE-083 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Antisense Oligonucleotide for Myotonic Dystrophy - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Antisense Oligonucleotide for Spinal Muscular Atrophy and Myotonic Dystrophy - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AOD-9604 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 ATYR-1940 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ISIS-DMPKRx - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 omigapil - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Pabparna - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 PRO-135 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PRT-01 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 PRT-300 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 RNAi Gene Therapy to Activate Myotilin for LGMD - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 RNAi Oligonucleotide for Myotonic Dystrophy - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 SB-308 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecule for Muscular Dystrophy and Other Muscle Disorders - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Small Molecule to Target RNA for Myotonic Dystrophy - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Small Molecules for CNS and Muscular Dystrophy Diseases - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Small Molecules for Dysferlinopathies - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Small Molecules for Myotonic Dystrophy Type 1 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Small Molecules to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 SRT-149 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 SRT-152 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Stem Cell Therapy for Muscular Dystrophy - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Stem Cell Therapy for Musculoskeletal and Hematological Disorders - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 trehalose - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 VAL-0411 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 VLT-001 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 VLT-002 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 VLT-003 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 VLT-004 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 VLT-005 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 VLT-014 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 VLT-015 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 VLT-016 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 VLT-017 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 VLT-025 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 ZP-042 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Muscular Dystrophy - Recent Pipeline Updates 97 Muscular Dystrophy - Dormant Projects 102 Muscular Dystrophy - Discontinued Products 103 Muscular Dystrophy - Product Development Milestones 104 Featured News & Press Releases 104 Oct 14, 2014: Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083 104 Jul 17, 2014: Santhera Repositions Omigapil in Congenital Muscular Dystrophy and Initiates Clinical Development Program with Public-Private Partners 104 Feb 25, 2014: VLT Biopharma gets the Orphan Drug designation for VLT015 105 Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy 106 Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells 107 Dec 03, 2012: Benitec Biopharma's Muscular Dystrophy Program Demonstrates Significant Gene Silencing 107 Sep 12, 2012: An important breakthrough in the fight against muscular dystrophies 108 Jul 09, 2012: New gene transfer strategy shows promise for limb girdle and other muscular dystrophies 109 Apr 11, 2012: Santhera Pharma Joins EU-funded EndoStem Consortium In Preparation For Clinical Study With Omigapil In Congenital Muscular Dystrophies 110 Dec 14, 2011: Calzada Announces New Applications For AOD9604 111 Appendix 112 Methodology 112 Coverage 112 Secondary Research 112 Primary Research 112 Expert Panel Validation 112 Contact Us 113 Disclaimer 113
List of Tables Number of Products under Development for Muscular Dystrophy, H2 2014 12 Number of Products under Development for Muscular Dystrophy - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Muscular Dystrophy - Pipeline by Acceleron Pharma, Inc., H2 2014 22 Muscular Dystrophy - Pipeline by aTyr Pharma, Inc., H2 2014 23 Muscular Dystrophy - Pipeline by Benitec Biopharma Limited, H2 2014 24 Muscular Dystrophy - Pipeline by Bioblast Pharma Ltd., H2 2014 25 Muscular Dystrophy - Pipeline by Calzada Limited, H2 2014 26 Muscular Dystrophy - Pipeline by Evotec AG, H2 2014 27 Muscular Dystrophy - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 28 Muscular Dystrophy - Pipeline by Fate Therapeutics, Inc., H2 2014 29 Muscular Dystrophy - Pipeline by Genethon, H2 2014 30 Muscular Dystrophy - Pipeline by Genzyme Corporation, H2 2014 31 Muscular Dystrophy - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 32 Muscular Dystrophy - Pipeline by Marina Biotech, Inc., H2 2014 33 Muscular Dystrophy - Pipeline by Novogen Limited, H2 2014 34 Muscular Dystrophy - Pipeline by Prosensa Therapeutics B.V., H2 2014 35 Muscular Dystrophy - Pipeline by Prothelia, Inc., H2 2014 36 Muscular Dystrophy - Pipeline by SanBio, Inc., H2 2014 37 Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2014 38 Muscular Dystrophy - Pipeline by Sarepta Therapeutics, Inc., H2 2014 39 Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 40 Muscular Dystrophy - Pipeline by Valentia Biopharma S.L., H2 2014 41 Muscular Dystrophy - Pipeline by Zambon Company S.p.A., H2 2014 42 Assessment by Monotherapy Products, H2 2014 43 Number of Products by Stage and Target, H2 2014 45 Number of Products by Stage and Mechanism of Action, H2 2014 47 Number of Products by Stage and Route of Administration, H2 2014 49 Number of Products by Stage and Molecule Type, H2 2014 51 Muscular Dystrophy Therapeutics - Recent Pipeline Updates, H2 2014 97 Muscular Dystrophy - Dormant Projects, H2 2014 102 Muscular Dystrophy - Discontinued Products, H2 2014 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.